Conservative Management of Low Risk Superficial Bladder Tumors

Pruthi, Raj S.; Baldwin, Nathan; Bhalani, Vishal; Wallen, Eric

doi:10.1016/j.juro.2007.08.171

Cited by 69 publications

(38 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bladder cancer is a common type of genitourinary cancer and approximately 70% of cases are superficial (10,11). Currently, the main therapy used to treat bladder cancer is transurethral electroresection of bladder tumors (TURBT) or partial cystectomy.…”

Section: Discussionmentioning

confidence: 99%

“…However, due to the natural or acquired drug resistance of tumor cells, the instillation of a single drug often fails to prevent recurrence. Although combined chemotherapy may achieve a better result than single drug instillation, the rate of recurrence remains high (11,12). Therefore, it is necessary to develop drugs with a novel antitumor mechanism.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

TAT-Apoptin induces apoptosis in the human bladder cancer EJ cell line and regulates Bax, Bcl-2, caspase-3 and survivin expression

Wang

Fan

et al. 2012

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. In order to identify the antitumor effect of TAT-Apoptin on the human bladder cancer EJ cell line and study its impact on the expression of the apoptosis-related genes bax, bcl-2, caspase-3 and survivin, the MTT assay, real-time quantitative PCR and western blot analysis were used in this study. The results of the MTT assay indicated that TAT-Apoptin was able to inhibit the proliferation of EJ cells in a dose-dependent manner. The expression of Bax, Bcl-2, Caspase-3 and Survivin mRNA and protein following the treatment of the EJ cells with TAT-Apoptin (0.1, 0.5, 1, 10, 50 and 100 µg/ml) for 24, 48 and 72 h was analyzed. Cell proliferation was significantly different after treatment with the various concentrations of TAT-Apoptin and the durations of treatment. The level of expression of Bcl-2 and Survivin in EJ cells decreased significantly, while that of Bax and Caspase-3 increased significantly at the mRNA and protein levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

TAT-Apoptin induces apoptosis in the human bladder cancer EJ cell line and regulates Bax, Bcl-2, caspase-3 and survivin expression

Wang

Fan

et al. 2012

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Tras la evaluación inicial en atención primaria el paciente es remitido al servicio de urología para completar el estudio y ser diagnosticado de tumor vesical. El tratamiento conservador de los tumores Ta de bajo grado en pacientes de edad avanzada y con comorbilidades mé-dicas es una realidad en diferentes instituciones para evitar RTU repetitivas, sin embargo deben someterse a revisiones periódi-cas exhaustivas para el control de su enfermedad (8). Dentro del manejo y tratamiento conservador del cáncer vesical superficial de bajo riesgo se encuentra la ablación o fulguración con láser que en los pocos estudios realizados hasta la fecha se ha mostrado una técnica eficaz y segura sobretodo en pacientes ancianos y de alto riesgo quirúrgico (9).…”

Section: Discussionunclassified

Pre and postoperative care for the outpatient fulguration in superficial bladder tumor. What should know the primary care physician?

Cano-García¹,

Aparicio²,

Hidalgo-Agulló³

et al. 2014

Actual. Med.

View full text Add to dashboard Cite

Cuidados pre y postoperatorios en la fulguración ambulatoria del tumor vesical superficial. ¿Qué debe conocer el médico de atención primaria? ResumenIntroducción: El objetivo de este trabajo es transmitir al médico de atención primaria los cuidados pre y postoperatorios en la fulguración con láser holmium de la recidiva del tumor vesical superficial. Material y Métodos: Estudio descriptivo de una cohorte de pacientes, llevado a cabo en el Hospital Universitario Morales Meseguer, Murcia (España). Se incluyen 37 pacientes con recidiva de tumor vesical superficial de bajo riesgo, sometidos a fulguración con láser de holmium. Se incluyen en el estudio pacientes con tumor papilar, tamaño ≤15 mm, menos de 5 tumores y sin alteraciones en la coagulación ni alergias a anestésicos locales. Se entregan recomendaciones pre y postoperatorias al paciente que debe conocer el médico de atención primaria, previa y tras la intervención (fulguración vesical ambulatoria con láser de holmium). Se miden complicaciones, dolor tras el procedimiento, satisfacción del paciente. Resultados: La edad media de los pacientes fue de 69.2 años, siendo el 86.5% hombres. El número de lesiones fue de 1.5 ± 0.8 y el tamaño global medio de 5.5 ± 2.7 mm. El tiempo medio de realización del procedimiento endoscópico fue de 12 ± 4.3 minutos. El 100% de los pacientes presentó puntuación en la escala visual analógica del dolor ≤ 3. Sólo 1 caso de hematuria que se resolvió de forma conservadora. Conclusión: El tratamiento con láser holmium de la recidiva tumoral vesical superficial de bajo riesgo de forma ambulatoria es seguro, precisa de profilaxis antibiótica, control del dolor y especial atención a efectos adversos que suelen ser leves. AbstractIntroduction: The objective of this work is to inform to primary care the pre and postoperative care in holmium laser fulguration of superficial bladder tumor recurrence. Methods: A descriptive study of a cohort of patients, conducted at the University Hospital Morales Meseguer, Murcia (Spain). 37 patients with superficial bladder tumor recurrence undergoing holmium laser fulguration are included. Included in the study patients with papillary tumor size ≤ 15 mm, less than 5 tumors without coagulation disorders or allergies to local anesthetics. Pre and postoperative recommendations are given to the patient to know the family physician, after care and after surgery (outpatient bladder holmium laser fulguration). Complications, pain after the procedure and patient satisfaction were measured. Results: The mean age of the patients was 69.2 years, with 86.5% male. The number of lesions was 1.5 ± 0.8 and the overall average size of 5.5 ± 2.7 mm. The average time for completion of the endoscopic procedure was 12 ± 4.3 minutes. 100% of patients had scores on the visual analog pain scale ≤ 3. Only 1 case of hematuria that resolved conservatively. Conclusion: Holmium laser treatment of in low-risk superficial bladder tumor recurrence ambulatory safe, requires antibiotic prophylaxis, pain management and attention to side ef...

show abstract

“…Bladder cancer is one category of common genitourinary cancers in china, and about 70 percent of which is superficial cancer (Gu et al, 2003;Pruthi et al, 2008). Nowadays, the major therapy of bladder cancer is transurethral electroresection of bladder tumors (TURBT) or partial cystectomy.…”

Section: Discussionmentioning

confidence: 99%

Apoptin Induces Apoptosis in Human Bladder Cancer EJ and BIU-87 Cells

Zhan

Wang²,

Wang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The prokaryotic expression vector of Apoptin pBV220/ Apoptin was made by our institute (Yunnan Institute of Urology), the eukaryotic expression vector PCDNA3 and gene engineer bacteria E.coli DH-5α were provided by the Biological Institute of Chinese Medical Academy. The restriction endonuclease BamH I, Xhol, T4 DNA ligase, dNTP, pfuDNA Polymerase and DNA marker DL-2000 were bought from the TaKaRa company; the RPMI-1640 cell culture medium, the lipofectamineTM2000 Reagent and the RT-PCR kit were bought from Invitrogen company; the fetal bovine serum was came from Hyclone company; the plasmid extraction kit from OMEGA company; the Tunel Kit from Backman Coulter company,

show abstract

Conservative Management of Low Risk Superficial Bladder Tumors

Cited by 69 publications

References 10 publications

TAT-Apoptin induces apoptosis in the human bladder cancer EJ cell line and regulates Bax, Bcl-2, caspase-3 and survivin expression

TAT-Apoptin induces apoptosis in the human bladder cancer EJ cell line and regulates Bax, Bcl-2, caspase-3 and survivin expression

Pre and postoperative care for the outpatient fulguration in superficial bladder tumor. What should know the primary care physician?

Apoptin Induces Apoptosis in Human Bladder Cancer EJ and BIU-87 Cells

Contact Info

Product

Resources

About